New pieces of a puzzle: The current biological picture of MPN

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 2, 2012, Pages 415-422

  Kleppe, Maria ^a   Levine, Ross L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Epigenetics; JAK2; Leukemia; MPN; Signaling; STAT3

Indexed keywords

BCR ABL PROTEIN; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; INHIBITOR OF DIFFERENTIATION 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE PIM 1; PROTEIN TYROSINE PHOSPHATASE; RAF PROTEIN; RAS PROTEIN; STAT PROTEIN;

ANEMIA; DRUG TARGETING; GENETIC ASSOCIATION; HUMAN; JAK2 GENE; LEUKEMOGENESIS; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; MUTATOR GENE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

ANIMALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84864779559     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.07.002     Document Type: Review

References (109)

1. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N. Engl. J. Med. 2009, 361:1872-1885.
2. Wadleigh M., Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int. J. Hematol. 2010, 91:174-179.
3. Levine R.L., Pardanani A., Tefferi A., Gilliland D.G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 2007, 7:673-683.
4. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22:14-22.
5. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J.T., Morra E., Vannucchi A.M., Mesa R.A., Demory J.L., Barosi G., Rumi E., Tefferi A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
6. Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 2011, 86:1017-1026.
7. Tefferi A. Myelofibrosis with myeloid metaplasia. N. Engl. J. Med. 2000, 342:1255-1265.
8. Quintas-Cardama A., Kantarjian H., Cortes J., Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat. Rev. Drug Discov. 2011, 10:127-140.
9. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., Green A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
10. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
11. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:1779-1790.
12. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Frohling S., Dohner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J., Gilliland D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
13. Oh S.T., Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert. Rev. Hematol. 2010, 3:323-337.
14. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., Witte O.N., Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986, 233:212-214.
15. Shtivelman E., Zakut R., Canaani E. Frequent generation of nonrescuable reorganized Moloney murine sarcoma viral genomes. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:294-298.
16. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138.
17. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., DeAngelo D.J., Clark J.J., Lee S.J., Golub T.R., Wadleigh M., Gilliland D.G., Levine R.L. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3:e270.
18. Vainchenker W., Delhommeau F., Constantinescu S.N., Bernard O.A. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011, 118:1723-1735.
19. Oh S.T., Simonds E.F., Jones C., Hale M.B., Goltsev Y., Gibbs K.D., Merker J.D., Zehnder J.L., Nolan G.P., Gotlib J. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116:988-992.
20. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., Futreal P.A., Erber W.N., McMullin M.F., Harrison C.N., Warren A.J., Gilliland D.G., Lodish H.F., Green A.R. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 2007, 356:459-468.
21. Li J., Kent D.G., Chen E., Green A.R. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis. Model. Mech. 2011, 4:311-317.
22. Fathi A.T., Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv. Hematol. 2012, 2012:469592.
23. Pardanani A., Lasho T.L., Finke C.M., Mai M., McClure R.F., Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010, 24:1146-1151.
24. Tefferi A., Lasho T.L., Abdel-Wahab O., Guglielmelli P., Patel J., Caramazza D., Pieri L., Finke C.M., Kilpivaara O., Wadleigh M., Mai M., McClure R.F., Gilliland D.G., Levine R.L., Pardanani A., Vannucchi A.M. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010, 24:1302-1309.
25. Gelsi-Boyer V., Trouplin V., Adelaide J., Bonansea J., Cervera N., Carbuccia N., Lagarde A., Prebet T., Nezri M., Sainty D., Olschwang S., Xerri L., Chaffanet M., Mozziconacci M.J., Vey N., Birnbaum D. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 2009, 145:788-800.
26. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., Waghorn K., Zoi K., Ross F.M., Reiter A., Hochhaus A., Drexler H.G., Duncombe A., Cervantes F., Oscier D., Boultwood J., Grand F.H., Cross N.C. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 2010, 42:722-726.
27. Nikoloski G., Langemeijer S.M., Kuiper R.P., Knops R., Massop M., Tonnissen E.R., van der Heijden A., Scheele T.N., Vandenberghe P., de Witte T., van der Reijden B.A., Jansen J.H. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 2010, 42:665-667.
28. Abdel-Wahab O., Pardanani A., Patel J., Wadleigh M., Lasho T., Heguy A., Beran M., Gilliland D.G., Levine R.L., Tefferi A. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011, 25:1200-1202.
29. Brecqueville M., Cervera N., Adelaide J., Rey J., Carbuccia N., Chaffanet M., Mozziconacci M.J., Vey N., Birnbaum D., Gelsi-Boyer V., Murati A. Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer J. 2011, 1.
30. Brecqueville M., Rey J., Bertucci F., Coppin E., Finetti P., Carbuccia N., Cervera N., Gelsi-Boyer V., Arnoulet C., Gisserot O., Verrot D., Slama B., Vey N., Mozziconacci M.J., Birnbaum D., Murati A. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012, 51:743-755.
31. Dawson M.A., Bannister A.J., Gottgens B., Foster S.D., Bartke T., Green A.R., Kouzarides T. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009, 461:819-822.
32. Liu F., Zhao X., Perna F., Wang L., Koppikar P., Abdel-Wahab O., Harr M.W., Levine R.L., Xu H., Tefferi A., Deblasio A., Hatlen M., Menendez S., Nimer S.D. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011, 19:283-294.
33. Passamonti F., Rumi E., Pietra D., Della Porta M.G., Boveri E., Pascutto C., Vanelli L., Arcaini L., Burcheri S., Malcovati L., Lazzarino M., Cazzola M. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006, 107:3676-3682.
34. Vannucchi A.M., Antonioli E., Guglielmelli P., Pardanani A., Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008, 22:1299-1307.
35. Schindler C., Levy D.E., Decker T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 2007, 282:20059-20063.
36. Anand S., Stedham F., Gudgin E., Campbell P., Beer P., Green A.R., Huntly B.J. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood 2011, 118:1610-1621.
37. Walz C., Ahmed W., Lazarides K., Betancur M., Patel N., Hennighausen L., Zaleskas V.M., Van Etten R.A. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice. Blood 2012, 119:3550-3560.
38. Yan D., Hutchison R.E., Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012, 119:3539-3549.
39. Chen E., Beer P.A., Godfrey A.L., Ortmann C.A., Li J., Costa-Pereira A.P., Ingle C.E., Dermitzakis E.T., Campbell P.J., Green A.R. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010, 18:524-535.
40. Helgason C.D., Damen J.E., Rosten P., Grewal R., Sorensen P., Chappel S.M., Borowski A., Jirik F., Krystal G., Humphries R.K. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 1998, 12:1610-1620.
41. Moody J.L., Xu L., Helgason C.D., Jirik F.R. Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten+/-SHIP-/- mice: a novel model of myelodysplasia. Blood 2004, 103:4503-4510.
42. Akada H., Yan D., Zou H., Fiering S., Hutchison R.E., Mohi M.G. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010, 115:3589-3597.
43. Arcasoy M.O., Jiang X. Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. Br. J. Haematol. 2005, 130:121-129.
44. Laubach J.P., Fu P., Jiang X., Salter K.H., Potti A., Arcasoy M.O. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp. Hematol. 2009, 37:1411-1422.
45. Silva M., Richard C., Benito A., Sanz C., Olalla I., Fernandez-Luna J.L. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N. Engl. J. Med. 1998, 338:564-571.
46. Harir N., Pecquet C., Kerenyi M., Sonneck K., Kovacic B., Nyga R., Brevet M., Dhennin I., Gouilleux-Gruart V., Beug H., Valent P., Lassoued K., Moriggl R., Gouilleux F. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 2007, 109:1678-1686.
47. Wang Y., Fiskus W., Chong D.G., Buckley K.M., Natarajan K., Rao R., Joshi A., Balusu R., Koul S., Chen J., Savoie A., Ustun C., Jillella A.P., Atadja P., Levine R.L., Bhalla K.N. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009, 114:5024-5033.
48. Verstovsek S. JAK2 inhibitors and myeloproliferative neoplasms. Clin. Adv. Hematol. Oncol. 2008, 6:878-880. (896).
49. Khwaja A. PI3K as a target for therapy in haematological malignancies. Curr. Top. Microbiol. Immunol. 2010, 347:169-188.
50. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 2011, 11:761-774.
51. Esteban L.M., Vicario-Abejon C., Fernandez-Salguero P., Fernandez-Medarde A., Swaminathan N., Yienger K., Lopez E., Malumbres M., McKay R., Ward J.M., Pellicer A., Santos E. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol. Cell. Biol. 2001, 21:1444-1452.
52. Nakamura K., Ichise H., Nakao K., Hatta T., Otani H., Sakagami H., Kondo H., Katsuki M. Partial functional overlap of the three ras genes in mouse embryonic development. Oncogene 2008, 27:2961-2968.
53. Shannon K. The Ras signaling pathway and the molecular basis of myeloid leukemogenesis. Curr. Opin. Hematol. 1995, 2:305-308.
54. Beer P.A., Delhommeau F., LeCouedic J.P., Dawson M.A., Chen E., Bareford D., Kusec R., McMullin M.F., Harrison C.N., Vannucchi A.M., Vainchenker W., Green A.R. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010, 115:2891-2900.
55. Stegelmann F., Bullinger L., Griesshammer M., Holzmann K., Habdank M., Kuhn S., Maile C., Schauer S., Dohner H., Dohner K. High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations. Haematologica 2010, 95:666-669.
56. Kawamata N., Ogawa S., Yamamoto G., Lehmann S., Levine R.L., Pikman Y., Nannya Y., Sanada M., Miller C.W., Gilliland D.G., Koeffler H.P. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp. Hematol. 2008, 36:1471-1479.
57. Tokunaga M., Ezoe S., Tanaka H., Satoh Y., Fukushima K., Matsui K., Shibata M., Tanimura A., Oritani K., Matsumura I., Kanakura Y. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1. J. Biol. Chem. 2010, 285:31774-31782.
58. Darley R.L., Hoy T.G., Baines P., Padua R.A., Burnett A.K. Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells. J. Exp. Med. 1997, 185:1337-1347.
59. Darley R.L., Pearn L., Omidvar N., Sweeney M., Fisher J., Phillips S., Hoy T., Burnett A.K. Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood 2002, 100:4185-4192.
60. Zhang J., Socolovsky M., Gross A.W., Lodish H.F. Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood 2003, 102:3938-3946.
61. Zhang J., Lodish H.F. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors. Blood 2004, 104:1679-1687.
62. Braun B.S., Tuveson D.A., Kong N., Le D.T., Kogan S.C., Rozmus J., Le Beau M.M., Jacks T.E., Shannon K.M. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:597-602.
63. Birnbaum R.A., O'Marcaigh A., Wardak Z., Zhang Y.Y., Dranoff G., Jacks T., Clapp D.W., Shannon K.M. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol. Cell 2000, 5:189-195.
64. Largaespada D.A., Brannan C.I., Jenkins N.A., Copeland N.G. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat. Genet. 1996, 12:137-143.
65. Nawijn M.C., Alendar A., Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer 2011, 11:23-34.
66. Shay K.P., Wang Z., Xing P.X., McKenzie I.F., Magnuson N.S. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol. Cancer Res. 2005, 3:170-181.
67. Mizuno K., Shirogane T., Shinohara A., Iwamatsu A., Hibi M., Hirano T. Regulation of Pim-1 by Hsp90. Biochem. Biophys. Res. Commun. 2001, 281:663-669.
68. Krishnan N., Pan H., Buckley D.J., Buckley A. Prolactin-regulated pim-1 transcription: identification of critical promoter elements and Akt signaling. Endocrine 2003, 20:123-130.
69. Krumenacker J.S., Narang V.S., Buckley D.J., Buckley A.R. Prolactin signaling to pim-1 expression: a role for phosphatidylinositol 3-kinase. J. Neuroimmunol. 2001, 113:249-259.
70. Peltola K.J., Paukku K., Aho T.L., Ruuska M., Silvennoinen O., Koskinen P.J. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 2004, 103:3744-3750.
71. Cohen A.M., Grinblat B., Bessler H., Kristt D., Kremer A., Schwartz A., Halperin M., Shalom S., Merkel D., Don J. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk. Lymphoma 2004, 45:951-955.
72. Kim K.T., Baird K., Ahn J.Y., Meltzer P., Lilly M., Levis M., Small D. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005, 105:1759-1767.
73. Lilly M., Sandholm J., Cooper J.J., Koskinen P.J., Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 1999, 18:4022-4031.
74. Nosaka T., Kawashima T., Misawa K., Ikuta K., Mui A.L., Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 1999, 18:4754-4765.
75. Adam M., Pogacic V., Bendit M., Chappuis R., Nawijn M.C., Duyster J., Fox C.J., Thompson C.B., Cools J., Schwaller J. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res. 2006, 66:3828-3835.
76. Wernig G., Kharas M.G., Okabe R., Moore S.A., Leeman D.S., Cullen D.E., Gozo M., McDowell E.P., Levine R.L., Doukas J., Mak C.C., Noronha G., Martin M., Ko Y.D., Lee B.H., Soll R.M., Tefferi A., Hood J.D., Gilliland D.G. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13:311-320.
77. Grundler R., Brault L., Gasser C., Bullock A.N., Dechow T., Woetzel S., Pogacic V., Villa A., Ehret S., Berridge G., Spoo A., Dierks C., Biondi A., Knapp S., Duyster J., Schwaller J. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J. Exp. Med. 2009, 206:1957-1970.
78. Chen J.L., Limnander A., Rothman P.B. Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 2008, 111:1677-1685.
79. Zou H., Yan D., Mohi G. Differential biological activity of disease-associated JAK2 mutants. FEBS Lett. 2011, 585:1007-1013.
80. Gozgit J.M., Bebernitz G., Patil P., Ye M., Parmentier J., Wu J., Su N., Wang T., Ioannidis S., Davies A., Huszar D., Zinda M. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J. Biol. Chem. 2008, 283:32334-32343.
81. Akada H., Akada S., Gajra A., Bair A., Graziano S., Hutchison R.E., Mohi G. Efficacy of vorinostat in a murine model of polycythemia vera. Blood 2012, 119:3779-3789.
82. Schwemmers S., Will B., Waller C.F., Abdulkarim K., Johansson P., Andreasson B., Pahl H.L. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. Exp. Hematol. 2007, 35:1695-1703.
83. Puigdecanet E., Espinet B., Lozano J.J., Sumoy L., Bellosillo B., Arenillas L., Alvarez-Larran A., Sole F., Serrano S., Besses C., Florensa L. Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia. Leukemia 2008, 22:1368-1376.
84. Magnuson N.S., Wang Z., Ding G., Reeves R. Why target PIM1 for cancer diagnosis and treatment?. Future Oncol. 2010, 6:1461-1478.
85. Lelievre H., Cervera N., Finetti P., Delhommeau F., Vainchenker W., Bertucci F., Birnbaum D. Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators. Leukemia 2006, 20:1885-1888.
86. Walz C., Crowley B.J., Hudon H.E., Gramlich J.L., Neuberg D.S., Podar K., Griffin J.D., Sattler M. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J. Biol. Chem. 2006, 281:18177-18183.
87. Jakel H., Weinl C., Hengst L. Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control. Oncogene 2011, 30:3502-3512.
88. Gautier E.F., Picard M., Laurent C., Marty C., Villeval J.L., Demur C., Delhommeau F., Hexner E., Giraudier S., Bonnevialle N., Ducommun B., Recher C., Laurent G., Manenti S., Mansat-De Mas V. The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood 2012, 119:1190-1199.
89. Perk J., Iavarone A., Benezra R. Id family of helix-loop-helix proteins in cancer. Nat. Rev. Cancer 2005, 5:603-614.
90. Wood A.D., Chen E., Donaldson I.J., Hattangadi S., Burke K.A., Dawson M.A., Miranda-Saavedra D., Lodish H.F., Green A.R., Gottgens B. ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood 2009, 114:1820-1830.
91. Tam W.F., Gu T.L., Chen J., Lee B.H., Bullinger L., Frohling S., Wang A., Monti S., Golub T.R., Gilliland D.G. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood 2008, 112:1981-1992.
92. Jankovic V., Ciarrocchi A., Boccuni P., DeBlasio T., Benezra R., Nimer S.D. Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1260-1265.
93. Di Raimondo F., Azzaro M.P., Palumbo G.A., Bagnato S., Stagno F., Giustolisi G.M., Cacciola E., Sortino G., Guglielmo P., Giustolisi R. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 2001, 15:976-980.
94. Tefferi A., Vaidya R., Caramazza D., Finke C., Lasho T., Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J. Clin. Oncol. 2011, 29:1356-1363.
95. Medinger M., Skoda R., Gratwohl A., Theocharides A., Buser A., Heim D., Dirnhofer S., Tichelli A., Tzankov A. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br. J. Haematol. 2009, 146:150-157.
96. Lundberg L.G., Lerner R., Sundelin P., Rogers R., Folkman J., Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am. J. Pathol. 2000, 157:15-19.
97. Steurer M., Zoller H., Augustin F., Fong D., Heiss S., Strasser-Weippl K., Gastl G., Tzankov A. Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum. Pathol. 2007, 38:1057-1064.
98. Hoermann G., Cerny-Reiterer S., Herrmann H., Blatt K., Bilban M., Gisslinger H., Gisslinger B., Mullauer L., Kralovics R., Mannhalter C., Valent P., Mayerhofer M. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB J. 2012, 26:894-906.
99. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., Estrov Z., Fridman J.S., Bradley E.C., Erickson-Viitanen S., Vaddi K., Levy R., Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 2010, 363:1117-1127.
100. Tripodo C., Sangaletti S., Piccaluga P.P., Prakash S., Franco G., Borrello I., Orazi A., Colombo M.P., Pileri S.A. The bone marrow stroma in hematological neoplasms - a guilty bystander. Nat. Rev. Clin. Oncol. 2011, 8:456-466.
101. Tefferi A. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J. Cell. Mol. Med. 2009, 13:215-237.
102. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., Gilliland D.G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 2003, 348:1201-1214.
103. Longley B.J., Tyrrell L., Lu S.Z., Ma Y.S., Langley K., Ding T.G., Duffy T., Jacobs P., Tang L.H., Modlin I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 1996, 12:312-314.
104. Santos F.P., Verstovsek S. JAK2 inhibitors: what's the true therapeutic potential?. Blood Rev. 2011, 25:53-63.
105. Verstovsek S. Ruxolitinib: the first agent approved for myelofibrosis. Clin. Adv. Hematol. Oncol. 2012, 10:111-113.
106. Pardanani A., Vannucchi A.M., Passamonti F., Cervantes F., Barbui T., Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011, 25:218-225.
107. Verstovsek S. Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms. J. Clin. Oncol. 2011, 29:781-783.
108. Jedidi A., Marty C., Oligo C., Jeanson-Leh L., Ribeil J.A., Casadevall N., Galy A., Vainchenker W., Villeval J.L. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood 2009, 114:1842-1851.
109. Manshouri T., Estrov Z., Quintas-Cardama A., Burger J., Zhang Y., Livun A., Knez L., Harris D., Creighton C.J., Kantarjian H.M., Verstovsek S. Bone marrow stroma-secreted cytokines protect JAK2V617F-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011, 71:3831-3840.